Vertex Pharmaceuticals' SWOT analysis: stock outlook amid ... - MSN

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with a substantial market capitalization of $110.13 billion, continues to solidify its position as a leader in the biotechnology sector, with a ...

CouponFollow Extension

$110.13
OFF

Vertex Pharmaceuticals' SWOT Analysis: Stock Outlook Amid ... - MSN

3 weeks from now

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with a substantial market capitalization of $110.13 billion, continues to solidify its position as a leader in the biotechnology sector, with a ...

msn.com

$441.52
OFF

Vertex Pharmaceuticals' SWOT Analysis: Stock Poised For Growth

3 weeks from now

Based on InvestingPro's Fair Value analysis, the stock appears slightly overvalued at its current price of $441.52. The stock trades at relatively high multiples, with an EV/EBITDA ratio of …

msn.com

$441.52
OFF

Vertex Pharmaceuticals' SWOT Analysis: Stock Poised For Growth …

3 weeks from now

Based on InvestingPro's Fair Value analysis, the stock appears slightly overvalued at its current price of $441.52. The stock trades at relatively high multiples, with an EV/EBITDA ratio of …

investing.com

$110.13
OFF

Vertex Pharmaceuticals' SWOT Analysis: Stock Outlook Amid …

3 weeks from now

Jan 21, 2025 · Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with a substantial market capitalization of $110.13 billion, continues to solidify its position as a leader in the …

investing.com

$110.13
OFF

Vertex Pharmaceuticals' SWOT Analysis: Stock Outlook Amid …

3 weeks from now

Jan 21, 2025 · Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), with a substantial market capitalization of $110.13 billion, continues to solidify its position as a leader in the …

investing.com

$115
OFF

Vertex Pharmaceuticals' SWOT Analysis: Biotech Stock Poised For …

3 weeks from now

Dec 18, 2024 · Vertex Pharmaceuticals (NASDAQ: VRTX) Incorporated (NASDAQ:VRTX), with a substantial market capitalization of $115.6 billion, has established itself as a leader in the …

investing.com

$533
OFF

Vertex Pharmaceuticals' SWOT Analysis: Strong CF Franchise Fuels

3 weeks from now

The majority of analysts maintain positive ratings on Vertex stock, though price targets vary. As of January 27, 2025, Piper Sandler has set the highest price target at $533, while maintaining an ...

msn.com

$106
OFF

Vertex Pharmaceuticals' SWOT Analysis: Stock Outlook Balances ...

3 weeks from now

Jan 14, 2025 · Vertex Pharmaceuticals (NASDAQ: VRTX), with a substantial market capitalization of $106.4 billion, continues to solidify its position as a leader in the biotechnology …

investing.com

$106
OFF

Vertex Pharmaceuticals' SWOT Analysis: Stock Outlook Balances ...

3 weeks from now

Jan 14, 2025 · Vertex Pharmaceuticals (NASDAQ: VRTX), with a substantial market capitalization of $106.4 billion, continues to solidify its position as a leader in the biotechnology sector.

investing.com

3%
OFF

Vertex Pharmaceuticals' Next Big Chapter? Vertex Stock Surges On ...

3 weeks from now

2 days ago · On today's stock market, Vertex stock popped 5.3% to close at 461.68. Shares moved above their 200-day line for the first time since mid-December, MarketSurge shows. …

investors.com

$115
OFF

Vertex Pharmaceuticals' SWOT Analysis: Biotech Stock Poised For …

3 weeks from now

Dec 18, 2024 · Vertex Pharmaceuticals (NASDAQ: VRTX) Incorporated (NASDAQ:VRTX), with a substantial market capitalization of $115.6 billion, has established itself as a leader in the …

investing.com

$461
OFF

Vertex Pharma Stock Surges After FDA Approves Non-Opioid Pain …

3 weeks from now

2 days ago · Last November, I initiated coverage on Vertex Pharmaceutical Inc. (NASDAQ:VRTX) suggesting the stock as a strong buy around $461/share. This was due to the …

seekingalpha.com

3%
OFF

Alnylam Pharmaceuticals' SWOT Analysis: Stock Poised For Growth …

3 weeks from now

Recent Performance and Financial Outlook Alnylam's fourth quarter of 2024 demonstrated strong financial performance, with net product revenues reaching $452 million, 3% ahead of …

msn.com

FAQs about Vertex Pharmaceuticals' SWOT analysis: stock outlook amid ... - MSN Coupon?

Is Vertex Pharmaceuticals a leader in the biotechnology sector?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with a substantial market capitalization of $110.13 billion, continues to solidify its position as a leader in the biotechnology sector, with a strong focus on cystic fibrosis (CF) treatments and an expanding pipeline in pain management and gene therapies. ...

What is Vertex Pharmaceuticals' business model?

Vertex Pharmaceuticals is a renowned biotechnology company known for its ground-breaking research and development of innovative treatments for cystic fibrosis. This blog article examines its business model focusing on its strengths, weaknesses, opportunities, and threats through a SWOT analysis. ...

Are Vertex Pharmaceuticals insiders buying or selling more stock?

In the past three months, Vertex Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,178.00 in company stock. Only 0.20% of the stock of Vertex Pharmaceuticals is held by insiders. ...

Is Vertex Pharmaceuticals a publicly traded company?

Vertex Pharmaceuticals is a publicly traded company, meaning it is owned by shareholders who hold its stock. The mission statement of Vertex Pharmaceuticals is to discover, develop, and commercialize innovative medicines that transform the lives of people with serious diseases. ...

Is Vertex Pharmaceuticals (VRTX) a threat to its market share?

Vertex Pharmaceuticals Inc ( NASDAQ:VRTX) faces the constant threat of emerging competitors and novel therapies that could disrupt its market share. Although its focus on CF treatments is a strength, it also makes the company susceptible to shifts in market dynamics and patient preferences. ...

What challenges does Vertex Pharmaceuticals face?

Vertex Pharmaceuticals faces challenges in the regulatory environment for drug development and approval. The complex and constantly evolving nature of this environment may cause difficulties in obtaining regulatory approvals for its drugs or impact its business operations. Business Model, SWOT Analysis, and Competitors ...